3-(4-fluoro-phenyl)-1H-indazol-5-ylamine | 395099-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-fluoro-phenyl)-1H-indazol-5-ylamine
• 英文别名: 5-amino-3-(4-fluorophenyl)-1H-indazole；3-(4-Flurophenyl)-1H-Indazole-5-Ylamine；3-(4-fluorophenyl)-1H-indazol-5-amine
• CAS: 395099-48-6
• 化学式: C₁₃H₁₀FN₃
• 分子量: 227.241
• InChiKey: AGZGTCUSGGVSFV-UHFFFAOYSA-N

物化性质

• 沸点：
  479.5±30.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-fluoro-phenyl)-1H-indazol-5-ylamine 、 2-(甲基磺酰)苯磺酰氯化物 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 生成 N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide
  参考文献：
  名称：

  Substituted indazoles, compositions containing them, method of production and use

  摘要：

  取代吲唑，含有它们的组合物，生产方法和用途。本发明特别涉及具有激酶抑制活性的新型特定取代吲唑，具有治疗活性，特别是在肿瘤学方面。

  公开号：

  US20040106667A1
• 作为产物：
  描述：

  1-{[3-(4-fluorophenyl)-5-nitro(1H-indazolyl)]methoxy}-2-methoxyethane 在 palladium-carbon 氢气 、 盐酸 、 羟基甲酸酯 、 乙酸乙酯 、 NaSO4 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 乙醇 为溶剂， 反应 19.0h， 以to give the title compound (35 mg, 53% yield)的产率得到3-(4-fluoro-phenyl)-1H-indazol-5-ylamine
  参考文献：
  名称：

  Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds

  摘要：

  这项发明通常是针对使用吲唑类化合物治疗或预防慢性淋巴细胞白血病。该方法包括向需要治疗或预防慢性淋巴细胞白血病的患者给予有效量的吲唑类化合物，或其药学上可接受的盐或组合物。

  公开号：

  US20070060616A1

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。
• Efficient synthesis of 3-aryl-1H-indazol-5-amine by Pd-catalyzed Suzuki–Miyaura cross-coupling reaction under microwave-assisted conditions
  作者：Shengqiang Wang、Ruiyun Guo、Jingya Li、Dapeng Zou、Yangjie Wu、Yusheng Wu

  DOI：10.1016/j.tetlet.2015.04.024

  日期：2015.6

  Various 3-aryl-1H-indazol-5-amine derivatives were synthesized by Pd-catalyzed Suzuki–Miyaura cross-coupling reaction of (NH) free 3-bromo-indazol-5-amine with arylboronic acids under microwave-assisted conditions. The coupling reaction can be carried out under the conditions with dioxane/H2O as solvent, Pd(OAc)2 and RuPhos as catalyst system, and K3PO4 as a base in good to excellent yields.

  在微波辅助条件下，通过（Pd）催化的（NH）游离3-溴-吲哚-5胺与芳基硼酸的Suzuki-Miyaura交叉偶联反应，合成了各种3-芳基-1 H-吲哚5胺衍生物。可以在以二恶烷/ H 2 O为溶剂，Pd（OAc）2和RuPhos为催化剂体系，以K 3 PO 4为碱的条件下以良好或优异的产率进行偶联反应。
• Novel compounds that are ERK inhibitors
  申请人：Cooper Alan B.

  公开号：US20090118284A1

  公开（公告）日：2009-05-07

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明公开了式1.0的ERK抑制剂及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个带有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环上具有双键。所有其他取代基如本文所定义。本发明还公开了使用式1.0的化合物治疗癌症的方法。